ReviewFrontiers in cardiovascular medicine2026
The effectiveness and safety of oral Chinese patent medicines in treating myocardial infarction complicated with heart failure: a network meta-analysis of 12 interventions.
Review in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To systematically evaluate the effectiveness of different oral Chinese patent medicines (CPMs) combined with conventional treatment (CT) in the treatment of myocardial infarction with heart failure (MI-HF) using a Bayesian network Meta-analysis. Methods: Computerized searches were conducted in CNKI, WanFang, VIP, SinoMed, PubMed, EMbase, Web of Science, and the Cochrane Library for relevant randomized controlled trials (RCTs) published from database inception until October 15, 2025. The quality of the included studies was assessed using the Cochrane Risk of Bias tool (RoB2). Statistical analysis was performed using Stata 17.0 and RevMan 5.3. Results: A total of 42 RCTs were included, involving 12 oral CPMs, 6 outcome indicators and adverse reactions. In terms of improving the total clinical effective rate, Yixinshu capsules demonstrated the best therapeutic effect. Xintong oral liquid showed the best effect in improving LVEF and reducing LVESD. For reducing LVEDD, Shexiang Baoxin pill was optimal. Guanxin Shutong capsules were the most effective for lowering NT-proBNP and increasing the 6 MWT distance. Conclusion: Oral CPMs combined with CT significantly improve cardiac function, ventricular remodeling, and exercise tolerance in MI-HF. While short-term tolerability is favorable, poor reporting limits definitive safety conclusions. Notably, Xintong Oral Liquid, Guanxin Shutong Capsules, and Qili Qiangxin Capsules exhibit the most outstanding comprehensive benefits. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/, PROSPERO CRD420251234570.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.